explore -WSS

explore

author：comprehensive 2025-09-29 21:13:00 - browse：51

This image provided by Novo Nordisk in January 2023, shows packaging for the company's Wegovy drug. — Novo Nordisk via AP

PHILADELPHIA — Novo Nordisk’s obesity drug Wegovy notably cut the risk of heart attacks in a landmark cardiovascular trial that affirms the treatment offers health benefits beyond weight loss.

The company in August had announced that in this trial, called Select, Wegovy reduced the overall rate of major heart problems — heart attacks, stroke, or cardiovascular-related death — by 20%. That finding, which was the primary outcome the trial set out to study, was stronger than many were expecting and led Novo’s stock to surge.

But details of the study, including risk reductions for each specific heart complication, were not released until Saturday, when they were presented here — before a standing-room only crowd — as the first major session of the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Oak Street deal isn't the answer to health care's woes

focus

WSS

Data don't support strong claims for Covid

ALS treatment from Biogen, Ionis fails in study

STAT series 'Denied by AI' wins major journalism prizes

For pregnant people, addiction treatment shouldn't mean a call to child protective services

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Medicare Advantage's lean provider networks lead CMS complaints

hotspot

explore

hotspot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

STAT wants to know your pick for a great summer read or listen

At least 13 dead in Texas as scorching temps continue

Supreme Court to hear if Covid misinformation is protected speech

Anesthesiologist group: stop taking Ozempic before surgery

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

The high cost of giving birth even with insurance

STAT series 'Denied by AI' wins major journalism prizes

United colonoscopy coverage change 'may cost lives,' doctors say

A new initiative will help leaders fight the next pandemic

knowledge

Elevance PBM president out as customers face prescription chaos

Stopping antidepressants leads to symptoms for 1 in 6 patients

FDA approves Moderna’s RSV vaccine, its second licensed product

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

Finland to offer bird flu vaccine to select groups of people, a possible global first

focus

leisure time

focus

hotspot